HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
https://doi.org/10.24060/2076-3093-2013-0-4-16-22
Abstract
In this article results of the multicenter trial are displayed. Data of successful efficacy of trastuzumab treatment in HER2 positive gastric cancer patients has shown.
About the Authors
H. C. Chung
Yonsei Cancer Center,Yonsei University College of Medicine
Korea, Republic of
Seoul
Korea, Republic of
Seoul
Y-J. Bang
F. Hoffmann-La Roche
Korea, Republic of
Basel
Korea, Republic of
Basel
J. M. Xu
Affiliated Hospital (307 Hospital) Cancer Centre
China
China
Beijing
F. Lordick
China National Centre for Tumour Diseases
Germany
Germany
Heidelberg
A. Sawaki
Germany Aichi Cancer Centre
Japan
Nagoya
Japan
Nagoya
O. Lipatov
Bashkortostan Republican Clinical Oncology Dispensary
Russian Federation
Ufa
Russian Federation
Ufa
M. Lehle
F. Hoffmann-La Roche
Switzerland
Basel
Switzerland
Basel
М. Pickl
Roche Diagnostics Gmbh
Germany
Penzberg
Germany
Penzberg
J. Ruschoff
TARGOS Molecular Pathology Laboratory Gmbh
Germany
Kassel
Germany
Kassel
E. Van Cutsem
University Hospital Gasthuisberg
Belgium
Leuven
Belgium
Leuven
References
1. Barok M., Isola J., Palyi-Krekk Z. et al. Trastuzumab causes antibody-dependent cellular cytotoxicitymediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance // Mol. Cancer Ther. 2007. Vol. 6. P. 2065-2072.
2. Fujimoto Duchi K. et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models // Cancer Chemother. Pharmacol. 2007. Vol. 59. P. 795-805. 3. Hofmann M., Stoss O., Shi D., Buttner R., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study // Histopathology. 2008. Vol. 52(7). P. 797-805.
3. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world // J. Clin. Oncol. 2008. Vol. 24. P.2137-2150.
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N Engl. J. Med. 2001. Vol. 344(11). P.783-792
5. Smith I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial // Lancet. 2007. Vol. 369. P. 29-36.
6. Van Cutsem E., Kang Y., Chung H., Shen L., et al. Efficacy results from the ToGA trial: A phase III study of trastruzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) // JCO. 2009. Abstract 4509.
Review
For citations:
Chung H.C., Bang Y., Xu J.M., Lordick F., Sawaki A., Lipatov O., Lehle M., Pickl М., Ruschoff J., Cutsem E.V. HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL). Creative surgery and oncology. 2013;(4):16-22. (In Russ.) https://doi.org/10.24060/2076-3093-2013-0-4-16-22
Views:
705
Email this article 